Moneycontrol
HomeNewsOpinion‘Dharavi Model’ is the silver lining in Mumbai’s COVID-19 cloud

‘Dharavi Model’ is the silver lining in Mumbai’s COVID-19 cloud

It’s worthwhile to unpack the strategies that succeeded in Dharavi as they not only reveal much about the settlement, but also hold lessons for rest of Mumbai, and indeed the rest of India

July 03, 2020 / 12:39 IST
Story continues below Advertisement
Representative image

Dharavi, long and unfairly condemned as one of Mumbai’s sore spots, has thrown a surprise during this extremely challenging COVID-19 time. At the end of a difficult and tense April-to-June quarter, the number of positive cases declined, doubling rate of infections vastly improved, and the dreaded Coronavirus curve flattened. For once, Dharavi found itself in the good news section.

On April 1, when Dharavi recorded its first COVID-19 case and death, it seemed that cases would explode given its lack of sanitary facilities and super-high density which made social distancing impossible. The grim scenario of rapidly rising cases and deaths each day since then turned last month leaving Dharavi better off than most of Mumbai, though the battle against the virus is far from over.

Story continues below Advertisement

On July 1, there were 2,282 cases — barely three percent of Mumbai’s total — and nearly 80 deaths here in the world’s most dense urban settlement of nearly a million people packed into a maze of tiny, tightly-packed tenements, commercial spaces, narrow alleys and common washrooms.

It’s worthwhile to unpack the strategies that succeeded in Dharavi. They not only reveal much about the settlement, but also hold lessons for rest of Mumbai, indeed the country.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show